4D Molecular Therapeutics
FDMT
158 hedge funds and large institutions have $771M invested in 4D Molecular Therapeutics in 2026 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 62 increasing their positions, 37 reducing their positions, and 23 closing their positions.
3,338% more call options, than puts
Call options by funds: $7.25M | Put options by funds: $211K
68% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 37
64% more capital invested
Capital invested by funds: $471M → $771M (+$300M)
35% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 23
11.85% more ownership
Funds ownership: 99.16% → 111% (+12%)
4% more funds holding
Funds holding: 152 → 158 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$24.5M |
| 2 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
+$9.01M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.28M |
| 4 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$5.56M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.8M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$3.91M |
| 3 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$2.21M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.56M |
| 5 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$1.24M |
FDMT Hedge Fund Activity: Q2 2026 in Review
158 of the 8,295 institutional investors tracked by Wall St. Rank reported a position in 4D Molecular Therapeutics (FDMT) for Q2 2026, worth a combined $771M — up 64% from $471M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new FDMT positions and 23 closed out — a net gain of 8 holders — while 62 added to existing stakes and 37 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $24.5M. The largest seller was Federated Hermes, cutting an estimated $11.8M.
- 158 institutional investors held 4D Molecular Therapeutics (FDMT) as of Q2 2026, up from 152 in Q1 2026.
- Funds reported $771M of 4D Molecular Therapeutics stock for Q2 2026, up 64% quarter-over-quarter.
- 31 funds opened new 4D Molecular Therapeutics positions in Q2 2026 and 23 closed out, a net change of +8 holders.
- The largest 4D Molecular Therapeutics buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $24.5M added.
- The largest 4D Molecular Therapeutics seller in Q2 2026 was Federated Hermes, an estimated $11.8M sold.
Based on aggregated 13F filings for Q2 2026.